Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in … – Benzinga

Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in
Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with …

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.